Abstract
Clinical evidence suggests that melanocortin therapy by using adrenocorticotropin (ACTH) is effective in inducing remission of proteinuria in patients with idiopathic membranous nephropathy (MN) and even in those resistant to steroids or other immunosuppressants. Likewise, in passive Heymann's nephritis (PHN), a rat model of MN, ACTH and other non-steroidogenic melanocortins are able to ameliorate glomerular injury and proteinuria. However, the type of melanocortin receptor (MCR) mediating this beneficial effect as well as the underlying mechanism remains controversial.
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
